Sleep Disorder at High Altitude by Kong, Fanyi
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter
Sleep Disorder at High Altitude
Fanyi Kong
Abstract
In this chapter, we discuss the occurrence, mechanism, clinical manifestations,
outcomes, and managements of a commonly encountered sleep disorder of some-
one traveling in high altitude for working and sight-seeing. Humans ascending to
altitudes above 2500 m usually suffer from substantial disturbances in sleep quality
as difficulty in sleep onset, frequent awakenings, respiratory disturbance, and a
feeling of drowsiness on the next day. Data obtained from polysomnographic
studies demonstrated several variations of sleep architecture in those healthy
subjects ascending to high altitude during sleep, including periodic breathing and
decreased non-rapid eye movement deep sleep stage 3 and 4 (in new nomenclature
N3), which were usually accompanied by and the lowered arterial O2 and restricted
ventilation. Hypoxia is most severe during sleep and in correspondence to periodic
breathing and sleep disturbance at high altitude. Poor sleep quality impairs cogni-
tion and executive abilities at high altitude though it may largely be improved after
full time of acclimatization. Evidence-based choices for clinicians to treat sleep
disorder at high altitude are relatively scarce at present. Supplemental oxygen and
dietary nitrate are effective in alleviating nocturnal hypoxia. There is strong
evidence supporting the efficacy and safety of acetazolamide and nonbenzodiazepines
in minimizing periodic breathing and improving sleep quality at high altitude.
Keywords: sleep architecture, sleep disorder, sleep quality, periodic breathing,
high altitude, treatment
1. Introduction
Every year, thousands of people come from the lowlands to high altitude such
as the Qinghai-Tibetan plateau, the Andes, and the Alps, for sight-seeing and
mountaineering. Although identification on high altitude is controversial [1, 2]
(see Table 1), altitude illnesses do not generally occur until 2500 m altitude or
greater [2]. Currently, there are hundreds of thousands of non-native people
working and living in these areas at altitudes ranging from 4000 to 5072 m including
mountaineers, search and rescue personnel, and military personnel.
Poor sleep quality is a common experience for new arrivals at high altitude in the
days to weeks following acute ascent. They often encounter with increased awak-
enings, frequent brief arousals, a sense of suffocation relieved by a few deep
breaths, and resumption of sleep, which is now known as periodic breathing (PB).
Upon arising from sleep, the impression is one of greatly restless sleep. Poor sleep
quality at high altitude is one of the serious complaints in people with mountain
sickness and influences physical and mental well-being, which can manifest as
impaired cognitive abilities [3, 4] and poor daytime performance [5]. Up to now,
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there are no acceptable diagnostic criteria for sleep disorder at high altitude. It is
recognized as a symptom of mountain sickness rather than an altitude disease.
Here we discuss the features of sleep at high altitude with focus on the role and
causes of PB in altitude sleep disturbance, subjective changes in sleep quality,
objective variations in sleep architecture, and management of sleep disorder at high
altitude. We also discuss whether it is appropriate to name it high-altitude sleep
disorder (HASD) as one of the altitude-related illness in accordance with the
nomenclature of other high-altitude diseases.
2. Breathing disturbance during sleep at high altitude
One of the most important characteristics of sleep disorder at high altitude is PB,
which usually occurs at altitudes above 2000 m [6]. PB during sleep was first
recorded in 1886 by Mosso [7] and further observed by Douglas and Haldane in
1909 [8]. It is considered that under high altitude hypoxic circumstances, breathing
was stimulated by hypoxia, leading to hypocapnia and lessening of hypoxia, which
triggers apnea during sleep. Apnea, in turn, restores ventilatory by raising PCO2 and
increasing hypoxia, generating the periodic respiratory cycle. This cyclical
crescendo-decrescendo pattern periodicity usually consists of 2–4 breaths, sepa-
rated by an apnea of 5–15 s in duration from the next burst of 2–4 breaths. There-
fore, unstable breathing is the main characteristic of PB.
The extent of PB increased progressively as the altitude increased [9]. There is a
strong positive correlation between PB and severity of acute mountain sickness
(AMS) as assessed by Lake Louise (LL) score. With the increasing of altitude,
normal values for partial pressure of arterial (PaO2) decreased compared to sea
level, pH changing to respiratory alkalosis with concomitant hypocapnia [10].
Above 4000 m altitude, PB exists in most people, but this phenomenon may be
beneficial, because with the worsening of PB, a higher arterial oxygen saturation
(SaO2) was observed during sleep [10, 11]. After 3 months of acclimatization at
3800 altitude, PB could also be observed in lowlanders. Although acclimatized
lowlanders experienced PB more frequently than native Tibetans at 89–85% of SaO2
stage, there is no significant difference in total PB events occurring either in non-
rapid eye movement (NREM) or rapid eye movement (REM) stage [12]. See details
in Figure 1, periodic breathing during sleep between native Tibetans and acclima-
tized Han lowlanders at 3800 m altitude. Even for a longer time (13 months) of
camp in the Antarctic base Concordia (3800 m), PB prevailed for the major part of
sleeping time [13]. These findings from a cross-sectional and a longitudinal study
support our current understanding which assumes PB would not be largely relieved
after acclimatization.
The mechanism underlying this respiratory pattern for apnea and PB during
sleep in hypoxic environments is believed to be a reduction in the PaO2 and acid-
base adjustments. The procedure of PB may be summarized as conflicting dynamics
between hypoxic stimulation of ventilation and suppression of respiratory output
Davis et al. [1] Rolan [2]
High altitude Beyond 2400 m 2500 m–3500 m
Very high altitude Beyond 4000 m 3500 m–5800 m
Extremely high altitude Beyond 5500 m Beyond 5800 m
Table 1.
Identification of high altitude.
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from ensuing hypocapnia. These changes lead to alterations in chemoreflex control
and cerebrovascular responses to changes in arterial O2 which finally result in
hyperventilation. For lowlanders, acclimatization to high altitude magnifies these
changes. Briefly, an elevated chemosensitivity causes a more vigorous response to
the rise in PaCO2 while the apnea outweighs the improvements in the effectiveness
of ventilation in changing the arterial O2 caused by the chronic hypocapnia leading
to the occurrence of PB [14].
The severity of PB is determined to be aggravated by an increasing neural respira-
tory drive (NRD), which can be measured by the electromyogram of the diaphragm.
A sleep study in four healthy mountaineers performed at 3380, 4370, and 5570 m in
the Andes, Argentina, confirmed this hypothesis [15]. A high NRD at altitude leads to
a higher ventilation to maintain oxygenation, which results in more significant
hypocapnia. This triggers apneas and O2 desaturations, as indicated by the positive
correlation between the EMG of the diaphragm and the O2 desaturation index.
PB is considered to contribute to and/or be a result of sleep fragmentation by
frequent arousals which may be responsible for poor sleep quality following altitude
ascent. Sleep and arousals lead to greater breathing instability. Apnea is in
correspondence to an increase in PaCO2 and decrease in PaO2 and consequently
unstable ventilation. These changes in blood gases also lead to marked alterations in
cerebral blood flow (CBF) which, in turn, may result in a sudden elevation (with
reduced CBF) or reduction (with increased CBF) in brain stem pH.
Therefore, the uncomfortable sensation of sleep at high altitude is largely due to
respiratory disturbance arising from the physiologic ventilatory dilemma of acute
ascent, where stimulation by hypoxia alternates with inhibition by hypocapnic
alkalosis.
3. Poor subjective sleep quality at high altitude
3.1 Evaluation and prevalence of poor sleep quality at high altitude
Subjective sleep quality at high altitude is usually evaluated by a questionnaire,
e.g., sleep log questions, Pittsburgh Sleep Quality Index (PSQI), and Athens Insom-
nia Score (AIS). The prevalence of sleep disorder may differ considerably at altitude
Figure 1.
Periodic breathing during sleep between native Tibetans and acclimatized Han lowlanders at 3800 altitude.
Modified from Kong et al. [12].
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from observational studies. At a 3500 m hotel, 46% of 100 Iranian ski tourists
reported frequent awakenings and other subjective sleep disturbances [16]. At an
altitude of 3700 m in Lhasa, Tibet, 36.8% of 180 Chinese stationed soldiers reported
poor sleep quality as measured by PSQI [17]. Data analysis from the same sample
also indicated that poor sleepers (defined as PSQI > 5) were 1.45 times greater in
those with polycythemia than those without polycythemia [95% (confidence inter-
val) CI 1.82–2.56] [4]. Report from early pharmacologic treatment trials in acute
mountain sickness (AMS) suggested that 53–71% of participants reported difficulty
sleeping [18, 19]. Of note, despite the 3 months of acclimatization, a greater pro-
portion of poor sleepers were still observed in lowlanders stationed at 3800 altitude
than the native Tibetans (90.91 vs. 45.45%, P = 0.004) [12].
3.2 Sleep quality and severity of mountain sickness
Poor sleep quality at high altitude was one of the most frequently reported
symptoms in mountain sickness as assessed by the Lake Louise Symptom Ques-
tionnaire and the Qinghai Chronis Mountain Score [12], which are used to diagnose
AMS [20] and evaluate severity of chronic mountain sickness(CMS) [21], respec-
tively. This was confirmed by a study using PSQI and AIS which reports decreased
subjective sleep quality at high altitude, especially reduced general sleep quality and
prolonged sleep induction [22]. For workers rapidly transported from sea level to
high altitude, there are no statistically significant differences in polysomnographic
parameters between subjects with AMS and those without AMS [23].
Figure 2.
Sleep quality comparison among different CMS severity at 3996 altitude. Modified from Kong et al. [4].
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For people with CMS stationed at Tibet, the proportion of poor sleepers
(defined as PSQI > 5) with severe CMS was 12.54-fold higher than that of good
sleepers. See Figure 2, CMS severity comparison between “good” and “poor”
sleepers at 3996 m altitude. Subjects with CMS had higher scores in each sleep
component of the PSQI score, except the use of sleep medication. After adjusted
for CMS score, age, and education, poor sleep quality was determined to be an
independent predictor of impaired intelligence quotient [odds ratio (OR) 1.59,
95% CI 1.30–1.95] and short-term memory (OR 1.18, 95% CI 1.07–1.31).
Therefore, for people with CMS, the poorer the sleep quality, the worse was the
cognitive function [4].
4. Variation of sleep architecture at high altitude
Polysomnography (PSG) is the gold standard for investigating sleep architec-
ture. However, the technical complexity and logistic demands had brought restric-
tion on its utilization during altitude studies. Although there are several studies that
suggest wrist actigraphy-derived data on total sleep time, sleep efficiency and sleep
onset latency were similar to those of PSG [24]; actigraphy is insufficient in
detecting sleep stage and breathing events.
Objective assessment of sleep architecture at altitude by electroencephalogram
was first reported by Joern et al. in 1970 [25]. They found a near absence of stages 3
and 4 and a 50% reduction in rapid eye movement (REM) sleep and reported PB
and arousals in one subject. A later study in 1975 confirmed a decrease in deeper
sleep and increase in lighter sleep stages and brief arousals after ascending to an
altitude of 4300 m at the Pikes Peak when compared to subjects at low altitude [26].
Subsequent studies have generally confirmed the shift at altitude toward lighter
sleep stages, with a variable change in duration of REM sleep and increased awak-
enings associated with PB [27–30].
Alterations in objective sleep parameters have also been observed during accli-
matization. A recent literature review on high-altitude sleep concludes that during
rapid ascent to high altitude, there is a reduction in total sleep time, sleep efficiency,
and deep sleep (stages 3 and 4) (in new nomenclature N3) and a significant increase
in arousals and PB [31]. These variations are possibly high altitude dependent, and
the effects tend to moderate with acclimatization [6]. Hypnograms of a partially
acclimatized lowlander sleeping and a native Tibetan sleeping at high altitude are
shown in Figures 3 and 4.
Although subjective sleep quality is impaired at high altitude, attempts to find a
correlation between objective and subjective measures have failed to find a connec-
tion [24]. One study investigated 63 participants who completed a 3-hour flight
from sea level to the South Pole (3200 m) and discovered no association between
self-reported sleep quality and sleep efficiency, nocturnal oxygen saturation, and
apnea/hypopnea index (AHI) obtained from PSG [32]. When assessed by LL score,
there was no significant correlation of the subjective sleep measurement compared
to sleep efficiency derived from PSG and actigraphy [24]. Another study investi-
gated 165 young male soldiers stationed in Tibet Plateau (3800 m) for at least
3 months. In a multiple regression model adjusted for age, service time, body mass
index, Epworth Sleepiness Scale, anxiety, and depression, sleep onset latency
(b = 0.08, 95% CI: 0.01–0.15) and NREM latency (b = 0.011, 95% CI: 0.001–0.02)
obtained from PSG were slightly positively correlated with global PSQI, while mean
nocturnal SpO2 (b = 0.79, 95% CI: 1.35 to 0.23) and time in stage 3 + 4 sleep
(b = 0.014, 95% CI: 0.001 to 0.028) was slightly negatively associated with
global PSQI [12].
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5. Differences in sleep architecture between lowlanders and native
highlanders at high altitude
5.1 Sleep patterns of high-altitude natives
Tibetans and Andeans are the native populations to the Tibetan and Andean
Plateaus descending from colonizers. Both populations have been exposed to the
hypoxic environmental stress of lifelong exposure to high altitude. But native
Tibetans and Andean highlanders exhibit different ways of adaptation to chronic
hypoxia [33]. Andean highlanders have blunted hypoxia ventilatory response
Figure 4.
Hypnogram of a 25-year-old native Tibetan sleeping at altitude of 3800 m. There is sufficient time in stage 4
sleep and scarce REM sleep.
Figure 3.
Hypnogram of a 27-year-old young man sleeping acclimatized for 11 months at altitude of 3800 m. Frequent
awake, less proportion of stage 4 and REM sleep might be observed.
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compared to Tibetans which is thought to be acquired and developed in adolescence
[34]. Native Tibetans were reported to have higher maximal oxygen uptake, greater
ventilation, and brisker hypoxic ventilatory responses to adapt to the hypoxic
environment at high altitude and, therefore, to have a better-quality sleep than Han
lowlanders [35] which may largely be attributed to genetic adaptations [36].
Few studies had compared sleep architecture between high-altitude dwellers and
non-native highlanders. An elder study investigated the Sherpa highlanders dwell-
ing above 3500 m. The Sherpas exhibited few PB with apnea due to low ventilatory
sensitivity to hypoxia at 5300 m altitude [37]. A later study reported the sleep
pattern of Peruvian Andeans situated at 4330 m altitude. Sleep architecture is
closely resembling to normal of people at sea level with significant amount of
NREM sleep and unimpaired REM sleep [38]. Contrary to the previous reports, a
recent study surveyed sleep architecture of Peruvian highlanders living in Puno at
3825 m. The highlanders had a longer time in total sleep time and increased wake-
after-sleep onset and arousal index but decreased sleep efficiency, which suggest
greater disturbances in sleep in highlanders compared with lowlanders [39].
5.2 Sleep architecture in partially acclimatized lowlanders
As we mentioned above, acclimatization would help lowlanders to relieve sleep
disturbance after ascending to high altitude. This could be supported by an earlier
study which claimed over 3 days of acclimatization over 4559 m resulted in a partial
recovery of sleep structure with increases in slow wave sleep and REM sleep and a
reduction in the arousal index [40].
But little is known whether prolonged hypoxia may help to improve sleep
architecture at high altitude. Animal studies showed that there was a 50%
reduction in the proportion of slow wave sleep and loss of REM sleep when rats
were chronically exposed to hypoxia environment simulating an altitude of 5000 m
[41, 42]. A clinical study conducted in Shangri-La, which has an altitude of 3800 m,
surveyed the differences in sleep architecture between native Tibetans’ and Han
lowlanders’ stations for at least 3 months. After adjusted for the length of stay at
altitude, significant differences in lower mean nocturnal SpO2 and shorter time
in NREM sleep were determined in acclimatized lowlanders than the native
Tibetans [12]. Figure 5 indicates a decreased nocturnal artery oxygen of a 3-month
acclimatized lowlander. So, it is reasonable to conclude that the effect of
prolonged acclimatization to hypoxia is limited in relieving hypoxemia and
improving deep sleep which might be an explanation for the impaired cognition
brought about by poor sleep.
Figure 5.
Decreasing in artery oxygen during sleep of a 24-year lowlander acclimatized for 3 months at 3800 altitude.
The lowest SaO2 is 83% and the mean SaO2 is 92%.
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6. Is sleep disorder an altitude-related illness?
Studies on sleep disorder at high altitude from the above reviewed scientific
literature confirm the assumption that altitude-related illness including AMS and
HAPE may deteriorate sleep quality either directly or indirectly through complaints
of headache, hard breathing, cough, etc. It is widely accepted that HAPE usually
develops within 2–4 days after quickly ascending to high altitude, but sleep in the
first night at altitude may have been affected. Both susceptible HAPE subjects
and healthy mountaineers without HAPE revealed a major reduction in sleep
efficiency and in NREM stage 3 and 4 sleep (in new nomenclature N3) in the
first night after the ascent to 4559 m within 1 day [43]. The deteriorated
ventilation and intermittent hypoxia associated with PB in the first 1–2 nights at
high altitude with the associated elevation of pulmonary artery pressure may
promote the subsequent development of HAPE in susceptible subjects. Thus, the
occurrence of sleep disorder is prior to and/or independent of HAPE but may
worsen due to HAPE.
Literature reports also provide empirical evidence that sleep disturbance was
discordant from other AMS symptoms and absent in 40% of cases with severe
headache, long considered a symptom of AMS. Since sleep disorder correlated
poorly with other symptoms of AMS, the sleep component had been removed from
the 2018 Lake Louise Acute Mountain Sickness Score [44].
Therefore, it is conceivable that sleep disorder should be viewed as an indepen-
dent altitude-related illness rather than a symptom of AMS despite the fact that it
may overlap other mountain sicknesses. In accordance with the nomenclature of
other high-altitude diseases [e.g., high altitude cerebral edema (HACE), high alti-
tude pulmonary edema (HAPE), etc.], high-altitude sleep disorder (HASD) might
be an appropriate name.
7. Treatment of HASD
Hypoxemia is the main reason and one of the primary independent contributors
to poor sleep quality at high altitudes [12]. In theory, correction of hypoxemia by
supplemental oxygen or pharmacological suppression of ventilation may have the
potential in treating sleep disorder at high altitude.
7.1 Supplemental oxygen
A case report tested the treatment effect of a nasal demand oxygen delivery
device on hypoxemia during sleep at high altitude in a 46-year-old male healthy
participant at an altitude of 4600 and 5700 m [45]. The participant received a
volume of oxygen delivery dose for 0, 16.7, 33.3, and 50 ml/s at random per pulse
for every 2 h during sleep period. Results of the study indicated an increase in
arterial blood oxygen saturation and decreases in tidal volume and AHI.
Another controlled trial employed a noninvasive ventilation mode named adap-
tive servo ventilation (ASV) to stabilize periodic breathing due to hypobaric hyp-
oxemia at an altitude of 3800 m, but it failed to affirm its efficacy in controlling
central sleep apnea during sleep. However, in their controlled group, supplemental
oxygen improved oxygen desaturation index and oxygen saturation, whereas it
reduced the arousal index and NREM stage 1 sleep. But neither ASV nor supple-
mental oxygen could improve subjective quality as measured by the Stanford Sleep
Questionnaire and LL score [46].
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In summary, based on current limited studies, supplemental oxygen does
improve arterial blood oxygen saturation but could not result to a better sleep
quality.
7.2 Diet therapy
Dietary nitrate (NO3), which is found in beetroot and other vegetables, and
inorganic NO3 salts have been shown to have vasodilatory properties [47] and also
to reduce oxygen uptake during exercise [48], suggesting NO3 supplementation
might play a physiological role during sleep at high altitude. A single-blind placebo-
controlled trial examined the effects of dietary NO3 supplementation on the
degree of sleep-related hypoxemia in healthy subjects at an altitude from 3700 to
4900 m. Each subject received two 70ml shots of either beetroot juice (5.0mmol
NO3 per shot) or placebo (0.003mmol NO3 per shot) over two consecutive
nights at altitude. Results of the study favored dietary nitrate in increasing fluctua-
tions in arterial O2 saturation during sleep at altitude in native lowlanders, but it
does not improve AHI or oxygenation [49].
7.3 Pharmacological agents
Previous reports suggested that only a few medications may be helpful at high
altitudes [50, 51], including theophylline, acetazolamide, zolpidem, zaleplon,
temazepam, and integripetal rhodiola herb, a traditional Chinese herb. However,
there are often several limitations on pharmacological selection at high altitudes in
clinical practice, as current sleeping medications prescribed for sleep disturbances
at sea level are not suggested to be used at altitude. For example, it is widely
accepted that benzodiazepines (BZDs) may cause hypoventilation, triggering
respiratory abnormalities during sleep [52–54]. Therefore, an ideal choice for med-
ication use at high altitude should neither deteriorate ventilation and oxygen satu-
ration nor affect sleep architecture.
7.3.1 Acetazolamide
Acetazolamide is considered to increase ventilation and oxygenation, effectively
reducing PB by approximately 50% [55]. A meta-analysis of randomized controlled
trials determined that acetazolamide improves sleep apnea at high altitude by
decreasing AHI and percentage of PB time and increasing nocturnal oxygenation.
Results from clinic trials also suggested that a 250 mg daily dose may be as effective
as higher daily doses for healthy trekkers [56].
7.3.2 Non-benzodiazepines
The efficacy and safety of zolpidem and zaleplon in treating sleep disturbances
at high altitude had been confirmed by several well-designed clinic trials [57–60]. A
recent meta-analysis of randomized placebo-controlled trials revealed that zaleplon
and zolpidem improved the total sleep time, sleep efficiency, and stage 4 sleep
duration, whereas they decreased the wake-after-sleep onset without impairing
ventilation [61] (data are shown in Figure 6).
There was no significant difference in ventilation as measured by SpO2 and PB
between participants administered with zaleplon or zolpidem and placebo [58–60].
Furthermore, participants who were administered with zaleplon or zolpidem
expressed a significant improvement in the subjective sleep quality, which was
9
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measured by sleep log question [59, 60] and PSQI (4.15  2.76 in zolpidem group
vs. 6.58  3.98 in placebo group, P = 0.047) [60].
7.3.3 Benzodiazepines
Benzodiazepine use in this environment is controversial. Early studies showed
that 1 mg of oral loprazolam did not worsen either slow wave sleep depression or
apnea and allowed normal sleep reappearance after acclimatization [28, 62]. Later, a
randomized, double-blind, placebo-controlled trial conducted at 3000 m altitude
validated PaO2 decreasing and PaCO2 increasing significantly 1 hour after 5 mg of
oral diazepam [63], which suggests that it may cause hypoventilation.
On the contrary, temazepam, a short-acting benzodiazepine, was recommended
to be safely used by the International Climbing and Mountaineering Federation
MedCom Consensus Guide [51]. However, the effect of temazepam on the objective
sleep parameters was inconsistent. Nicholson et al. [64] reported that temazepam
significantly shortened the mean sleep onset latency and increased the amount of
the REM sleep, whereas Nickol et al. [65] reported no differences in the actigraphy-
derived sleep parameters. Results on oxygen saturation and PB from the aforemen-
tioned studies were also inconsistent. When compared to the placebo, temazepam
showed no significant effect on mean oxygen saturation, yet PB significantly
decreased [66]. Although Nickol et al. [65] reported that temazepam could decrease
Figure 6.
Summary of non-benzodiazepines in improving sleep architecture at high altitude. Modified from
Kong et al. [61].
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median oxygen saturation, it did not significantly reduce PB during sleep. Because
of the inconsistencies in the reported variables, no confirming conclusions can be
drawn from available evidence.
To sum up, the use of benzodiazepines should be discouraged at high altitude
due to the nocturnal hypoventilation nature of these agents. The efficacy and safety
of temazepam need further confirmation by well-designed placebo-controlled trials.
7.3.4 Others
Additional drugs that may be helpful reported by case series include theophyl-
line and the integripetal rhodiola herb, which is a widely used traditional Chinese
herb in Tibetan areas. However, strong clinical evidence from randomized con-
trolled trials supporting the effectiveness and safety of these agents has not been
demonstrated.
7.4 Recommendations
Evidence from current available studies support the routing use of supplemental
oxygen during sleep to increase arterial blood oxygen saturation. Acute dietary
NO3 supplementation reduces flow limitation and induces more pronounced SaO2
desaturations during sleep at high altitude. Acetazolamide at 250 mg daily dose is
effective in reducing sleep apnea, decreasing AHI and PB, and increasing nocturnal
oxygenation. Both zaleplon and zolpidem improved the objective sleep architecture
without impairing ventilation.
8. Conclusions
Our understanding on sleep disorder at high altitude is still limited. Mountain
tourists commonly complain about subjective sleep disturbances with difficulty in
onset of sleep and frequent awakenings in the first few nights at altitude. But those
subjective sensations of poor sleep neither are associated with severity of mountain
sickness nor tend to disappear after long exposure to high altitude. And conse-
quently, cognitive function was impaired.
There is no reliable evidence that support the consistency between self-report
sleep quality and sleep parameters obtained from PSG. The most frequently reported
changes in sleep architecture at high altitude are detected by PSG including a decrease
in NREM sleep and occurrence of PB. Different patterns of adoption to hypoxic
environment exist among native highlanders. For lowlanders ascending to high alti-
tude, acclimatization would be beneficial in relieving hypoxemia and improving deep
sleep; however, PB would not be largely relieved after acclimatization.
The occurrence of HASD is prior to most altitude-related diseases and would last
for a longer time. We strongly suggest future study to consider it as an independent
high-altitude illness as it had been removed from the diagnosing and managing of
AMS by the International Society of Mountain MedicineWorld Congress Committee.
The treatment principle of HASD should not deteriorate nocturnal ventilation
and SaO2 or affect sleep architecture. The following evidence-based choices are
recommended. Effective treatments for altitude-related nocturnal hypoxemia
include dietary NO3 supplementation before sleep and supplemental oxygen
during sleep. Medication for respiratory disturbance is 250 mg daily dose of oral
acetazolamide, which is beneficial in relieving sleep apnea, decreasing AHI and PB,
and promoting nocturnal oxygenation. Both zaleplon and zolpidem are optional
agents in improving the objective sleep architecture and subjective sleep quality
without impairing ventilation.
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